Hepatitis C and HIV

Unfortunately a high percentage of those affected with HIV are also infected with the Hepatitis C virus. It is believed that nearly forty percent of HIV sufferers also have HCV.  This is because both viruses are transmitted the same way. They can be passed along by the shared use of needles or other drug paraphernalia or by unprotected sex because they are both transferred by blood-to-blood transmissions.   This means that it is not a surprise that people will be coinfected, having both infections, but it definitely makes treating them more difficult. Especially since Hepatitis C., also known as HCV, makes HIV worse, though it is known that it does not interfere with the medications used to treat HIV.

Studies conducted on people who are coinfected have found that this group seems to suffer a higher proportion of cases of depression, not a surprise when you think of what they have to deal with in their lives. The concern is that those who are feeling this way may be more apt to mix up their medications or even forget to take them.

One of the most difficult treatment issues with someone who is coinfected can be which should be treated first the HIV or the HCV? This must be decided based on severity and the progress of each infection. If the Hepatitis C is showing only mild symptoms then the HIV should be treated first. Leaving HIV untreated for six months to a year could be very hard on the patient's body and could lead to further complications down the way. On the other hand if the cell counts are high enough and the HCV is problematic then treating the hepatitis would be helpful in the long run. This is especially true because the liver will then be able to deal better with the strong drugs that need to be taken for HIV.

Those who are coinfected are at risk for the Hepatitis C virus to be much worse than others who are fighting only the one virus. With both, the patient may find that serious liver disease progresses much faster. Liver failure can actually occur.  Drug therapy for those who are coinfected is successful twenty five to fifty percent of the time depending on which genotype the HCV is. The results are better with type two and three then type one.  The drugs that are necessary to treat HIV can be very hard on the liver and so make for one more reason that trying to treat the HCV is very important.

When someone is coinfected the viral levels of the hepatitis are much higher. This means that the spread of the infection becomes that much easier and so the patient must work harder to control this potential for spreading. Do not share anything that may have even the minutest amount of blood on it. That includes toothbrushes, facecloths or razors.
If you're coinfected, or someone you love is, be sure the physician is able to treat you for both these difficult viruses.

Hepatitis news on the Web

As death nears, hepatitis C victim to give videotaped deposition in Desai case - Las Vegas Review-Journal

As death nears, hepatitis C victim to give videotaped deposition in Desai case
Las Vegas Review-Journal
Rodolfo Meana, pictured here in 2008, is one of seven patients diagnosed with hepatitis C that has been genetically linked to the Endoscopy Center of Southern Nevada. Meana's doctors have told him he is terminally ill. » Buy this photo Dr. Dipak Desai ...

and more »

BioLineRx Licenses Another Hepatitis C Drug From Genoscience - Wall Street Journal

BioLineRx Licenses Another Hepatitis C Drug From Genoscience
Wall Street Journal
BioLineRx Ltd. (BLRX) licensed another Hepatitis C treatment from French biotechnology company Genoscience, as the Israeli-based biopharmaceutical company expands into the field of Hepatitis C therapeutics. Hepatitis C is a blood-borne infection of the ...
BioLineRx In-Licenses Second Oral Hepatitis C TreatmentMarketWatch (press release)
BiolineRX signs second hepatitis C licensing dealGlobes

all 24 news articles »

BioLineRx shares soar (again) on hep C pact; Anacor shares slide after GSK ... - FierceBiotech

BioLineRx shares soar (again) on hep C pact; Anacor shares slide after GSK ...
FierceBiotech
Article | Follow @FierceBiotech @JohnCFierce: So does BioLineRx see itself as a hep C co. now that it has in-licensed a 2nd program, or is this about share price? Release | Follow @JohnCFierce @FierceMedDev: DNA-sequencing penetrates Norway's ...

and more »

Gilead Sciences Jumps on Hepatitis C Data - Pharmaceutical Processing

Gilead Sciences Jumps on Hepatitis C Data
Pharmaceutical Processing
NEW YORK (AP) — Shares of Gilead Sciences Inc. jumped Friday after the company reported further progress of GS-7977, a newly-acquired hepatitis C treatment still in clinical testing. THE SPARK: Gilead said Thursday that in a clinical trial, ...
Does Anavex Life Sciences (AVXL) Have the Next Big Thing Big Pharma Wants?SmallCap Network
Positive Clinical Trial Results Boost Gilead the Most in Three Years – NASDAQ:GILDGalaxy Stocks
Gilead stock rises on potential hepatitis C cureSan Francisco Business Times (blog)
Proactive Investors USA & Canada -Seeking Alpha -CNBC.com
all 12 news articles »

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover - BusinessWeek

RTT News

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
3 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
An all-oral hepatitis C drug may be one step closer to realityLagonian.com
Gilead Up 6% After Positive Hep-C TrialWall St. Cheat Sheet
DailyFinance -24/7 Wall St.
all 63 news articles »

Culture: Impact of war on language (155) - Egyptian Gazette

Culture: Impact of war on language (155)
Egyptian Gazette
In several studies of Veteran's Affairs (VA) Medical Centre patients, we find that 8-9% are positive for hepatitis C antibodies. Some VA Medical Centres had 10-20% of patients with hepatitis C antibodies. According to Dr Bradford Waters, Professor of ...

Idenix gets good news on hep C trial, but can't compete with Gilead - FierceBiotech

Citybizlist

Idenix gets good news on hep C trial, but can't compete with Gilead
FierceBiotech
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster ...
Idenix Falls Casualty to Gilead Hep C HooplaTheStreet.com
Idenix: FDA lifts partial hold on hepatitis C drugMarketWatch
Idenix Says FDA Lifts Partial Hold On Hepatitis Drug IDX184; But Stock DownNASDAQ
PR Newswire (press release)
all 31 news articles »

Vertex Hep C Sales Growth Nears End - TheStreet.com

Vertex Hep C Sales Growth Nears End
TheStreet.com
(TheStreet) -- Vertex Pharmaceuticals'(VRTX) fourth-quarter earnings report Thursday may represent the high-water sales mark for the hepatitis C drug Incivek -- with prescriptions already declining just seven months after launch.
Vertex Falls as Analyst Cuts Hep C Sales Estimate: Boston MoverBusinessWeek
Vertex Falls as Analyst Cuts Sales Estimates on Hepatitis C PillBloomberg
Vertex shares drop as analyst cools on high-flying hep C drugBoston Business Journal
LocalizedUSA -Financial News Network Online
all 15 news articles »

Hepatitis Research May Benefit From Stem Cells - Medical News Today

MD News

Hepatitis Research May Benefit From Stem Cells
Medical News Today
Hepatitis C is a viral disease that leads to inflammation and organ failure. However, researchers are puzzled as to why some individuals are very susceptible to the disease, while others are not. Researchers believe they could find out how genetic ...
Personalized Liver Cells Support Hepatitis C VirusDoctors Lounge

all 5 news articles »

New Study of Interferon-free HCV Therapy Hailed as 'Watershed Moment' in Hep C ... - Gastroenterology & Endoscopy News

Gastroenterology & Endoscopy News

New Study of Interferon-free HCV Therapy Hailed as 'Watershed Moment' in Hep C ...
Gastroenterology & Endoscopy News
by Christina Frangou A combination therapy including two investigational direct-acting antiviral agents (DAAs)—asunaprevir and daclatasvir—suppressed hepatitis C virus (HCV) genotype 1 infection in a majority of patients who had previously not ...


Google News